

1 **Title: GRAd-COV2, a gorilla adenovirus based candidate vaccine against**  
2 **COVID-19, is safe and immunogenic in young and older adults**

3 **Authors:** Simone Lanini<sup>1†</sup>, Stefania Capone<sup>2†</sup>, Andrea Antinori<sup>1</sup>, Stefano Milleri<sup>3‡</sup>, Emanuele  
4 Nicastrì<sup>1</sup>, Roberto Camerini<sup>2</sup>, Chiara Agrati<sup>1</sup>, Concetta Castilletti<sup>1</sup>, Federica Mori<sup>2</sup>, Alessandra  
5 Sacchi<sup>1</sup>, Giulia Matusali<sup>1</sup>, Roberta Gagliardini<sup>1</sup>, Virginia Ammendola<sup>2</sup>, Eleonora Cimini<sup>1</sup>,  
6 Fabiana Grazioli<sup>2</sup>, Laura Scorzoloni<sup>1</sup>, Federico Napolitano<sup>2</sup>, Maria Maddalena Piazzì<sup>1</sup>, Marco  
7 Soriani<sup>2</sup>, Aldo De Luca<sup>1</sup>, Simone Battella<sup>2</sup>, Andrea Sommella<sup>2</sup>, Alessandra M. Contino<sup>2</sup>,  
8 Federica Barra<sup>2</sup>, Michela Gentile<sup>2</sup>, Angelo Raggioli<sup>2</sup>, Yufang Shi<sup>4,5</sup>, Enrico Girardi<sup>1</sup>, Markus  
9 Maeurer<sup>6,7</sup>, Maria R. Capobianchi<sup>1</sup>, Francesco Vaia<sup>1</sup>, Mauro Piacentini<sup>8</sup>, Guido Kroemer<sup>9,10,11,12</sup>,  
10 Alessandra Vitelli<sup>2</sup>, Stefano Colloca<sup>2</sup>, Antonella Folgori<sup>2†</sup>, Giuseppe Ippolito<sup>1†‡\*</sup>

11  
12 **Affiliations:**

13 <sup>1</sup>Istituto Nazionale per Le Malattie Infettive Lazzaro Spallanzani IRCCS; Rome, Italy.

14 <sup>2</sup>ReiThera Srl; Rome, Italy.

15 <sup>3</sup>Centro Ricerche Cliniche di Verona srl; Verona, Italy.

16 <sup>4</sup>First Affiliated Hospital of Soochow University; Suzhou, Jiangsu, China.

17 <sup>5</sup>Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, Chinese  
18 Academy of Sciences; Shanghai, China.

19 <sup>6</sup>Division of Immunotherapy, ImmunoSurgery, Champalimaud Foundation; Lisboa, Portugal.

20 <sup>7</sup>I Medical Clinic, University of Mainz; Mainz, Germany.

21 <sup>8</sup>Department of Biology, University of Rome "Tor Vergata; Rome, Italy.

22 <sup>9</sup>Sorbonne Université, Institut Universitaire de France; Paris, France.

23 <sup>10</sup>Metabolomics and Cell Biology Platforms, Institut Gustave Roussy; Villejuif, France.

24 <sup>11</sup>Pôle de Biologie, Hôpital Européen Georges Pompidou; Paris, France.

25 <sup>12</sup>Department of Women's and Children's Health, Karolinska University Hospital, Stockholm,  
26 Sweden

27 \* Corresponding author. Email: [giuseppe.ippolito@inmi.it](mailto:giuseppe.ippolito@inmi.it)

28 † These authors contributed equally to this work

29 ‡ on behalf of the GRAd study group

30  
31 **One Sentence Summary:** GRAd-COV2, a candidate vaccine for COVID-19 based on a novel  
32 gorilla adenovirus, is safe and immunogenic in younger and older adults

33

34

35

36 **Abstract:**

37 Safe and effective vaccines against coronavirus disease 2019 (COVID-19) are urgently needed to  
38 control the ongoing pandemic. Although impressive progress has been made with several  
39 COVID-19 vaccines already approved, it is clear that those developed so far cannot meet the  
40 global vaccine demand. We have developed a COVID-19 vaccine based on a replication-  
41 defective gorilla adenovirus expressing the stabilized pre-fusion SARS-CoV-2 Spike protein,  
42 named GRAd-COV2. We aimed to assess the safety and immunogenicity of a single-dose  
43 regimen of this vaccine in healthy younger and older adults to select the appropriate dose for  
44 each age group. To this purpose, a phase 1, dose-escalation, open-label trial was conducted  
45 including 90 healthy subjects, (45 aged 18-55 years and 45 aged 65-85 years), who received a  
46 single intramuscular administration of GRAd-CoV2 at three escalating doses. Local and systemic  
47 adverse reactions were mostly mild or moderate and of short duration, and no serious AE was  
48 reported. Four weeks after vaccination, seroconversion to Spike/RBD was achieved in 43/44  
49 young volunteers and in 45/45 older subjects. Consistently, neutralizing antibodies were detected  
50 in 42/44 younger age and 45/45 older age volunteers. In addition, GRAd-COV2 induced a robust  
51 and Th1-skewed T cell response against the S antigen in 89/90 subjects from both age groups.  
52 Overall, the safety and immunogenicity data from the phase 1 trial support further development  
53 of this vaccine.

54

55 **Main Text:**

56 **INTRODUCTION**

57 The coronavirus disease 2019 (COVID-19) pandemic is the most significant international public  
58 health emergency occurred over a century. COVID-19 is caused by a novel human viral agent,  
59 the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that emerged in the  
60 People Republic of China at the end of 2019. Since its start, COVID-19 pandemic has already  
61 caused hundreds million cases of infections with about several million of fatalities worldwide.  
62 This unprecedented global health emergency has boosted international efforts to develop a  
63 vaccine and a multitude of platforms have been used including genetic vaccines based on  
64 mRNA, DNA and viral vectors. As of April 2021, there are 272 vaccine candidates. One hundred  
65 and eighty-six are in preclinical development and 86 in clinical development, of which 13 are

66 either authorized in emergency use or approved by different countries  
67 (<https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>).

68 However, COVID-19 vaccines rolled out so far cannot meet the global vaccine demand and there  
69 is an urgent need to develop additional safe and effective vaccines able to ramp up production to  
70 be included in worldwide vaccination campaigns.

71 We developed GRAd-COV2, a vaccine candidate based on an adenoviral vector derived from a  
72 group C Gorilla adenovirus that is made replication defective by deleting the E1 genomic region.  
73 GRAd-COV2 vaccine encodes for a full-length SARS-COV-2 Spike (S) protein. The S protein is  
74 the primary vaccine target for most COVID-19 vaccines as it is critical for viral cell entry  
75 through the human ACE2 receptor (1). The S gene cloned into GRAd-COV2 contains mutations  
76 that stabilize the S protein expressed in the host cell in a pre-fusion conformation for better  
77 exposure of epitopes important for antibody-mediated neutralization to the immune system (2,  
78 3). GRAd vector was selected based on its immunogenicity and manufacturability profile, in  
79 addition to the low frequency of anti-GRAd neutralizing antibodies in human sera compared  
80 with human adenovirus type 5 (4). We recently reported that a single dose of GRAd-COV2  
81 elicited strong immune responses, both humoral and cellular, in mice and rhesus macaques (4).  
82 These preclinical data supported the start of a first-in-human, dose escalation, phase 1 clinical  
83 trial in healthy younger and older adults to evaluate the safety and immunogenicity of GRAd-  
84 COV2.

85 Here we report the trial interim analysis results up to 4 weeks after vaccination.

86 The vaccine was well tolerated at all three dose levels explored,  $5 \times 10^{10}$  (low dose),  $1 \times 10^{11}$   
87 (intermediate dose) and  $2 \times 10^{11}$  (high dose) viral particles. Importantly humoral and T cell  
88 responses were readily induced at similar levels in the two age cohorts. Based on these results,  
89 we have initiated a phase 2/3 study that will evaluate the efficacy of either a single GRAd-COV2  
90 administration or a repeated dose regimen (NCT04791423).


91

## 92 **RESULTS**

### 93 **Volunteers screening and selection**

94 Between August 11 and September 20, 2020, 181 potential volunteers were evaluated for  
95 eligibility. Volunteers were screened in excess for speeding up enrollment and to comply with a  
96 strict staggering enrollment scheme. Of the 181 subjects screened, 91 (45 in younger adults  
97 cohort aged 18-55 and 46 in the older adults cohort, aged 65-85) were vaccinated. Fifty-five  
98 volunteers (30 in younger age cohort and 25 in the older age cohort) were excluded as they did  
99 not meet inclusion criteria and 35 (25 younger age cohort and 10 in the older age cohort) were  
100 not vaccinated as the time window between screening and vaccination was trespassed. Median  
101 age, gender distribution and other characteristics were well balanced within study arms both in  
102 the younger (Fig. 1A) and in the older adults (Fig. 1B) cohorts.

103 One vaccinated arm 1 volunteer had detectable levels of specific anti-N and S IgG since week 1  
104 after vaccination. As this finding suggested a natural (asymptomatic) infection with SARS-CoV-  
105 2, we excluded this subject from the immunogenicity analysis. One vaccinated arm 4 volunteer  
106 was found positive to anti-S IgG CLIA assay at baseline. The volunteer did not seroconvert to N,  
107 and was found negative when using a different assay (immunofluorescence), suggesting an  
108 unspecific reactivity to the CLIA. Being anti-S IgG CLIA, according to protocol, the main  
109 serological assay to follow vaccine induced anti-S IgG response, the volunteer was replaced with  
110 a subsequent one, and was included in the safety analysis but excluded from the immunogenicity  
111 assessment. Moreover, 3 additional volunteers (arms 2, 3 and 5) were excluded from IFN $\gamma$   
112 ELISpot analysis due to spontaneous IFN $\gamma$  production above acceptability range (Fig. 1).



113

114 **Fig. 1. Study sample selection and analysis.** Enrollment, study population characteristics,  
 115 treatment and follow-up of the (A) 45 volunteers enrolled in younger age cohort (aged 18-55  
 116 years), and of the (B) 46 volunteers enrolled in older age cohort (aged 65-85 years). Recorded  
 117 details include age at enrollment in years (median and range) and the body mass index (BMI). <sup>A</sup>  
 118 volunteers not vaccinated as they lost the time window between screening and vaccination visit;

119 <sup>B</sup> 1 volunteer excluded from humoral and cellular immunity analysis due SARS-CoV-2 infection  
120 immediately after/before vaccination; <sup>C</sup> volunteers excluded from ELISpot analysis only,  
121 because of high non-specific IFN $\gamma$  secretion. <sup>D</sup> 1 volunteer excluded from immunogenicity  
122 analysis and replaced, due to unspecific reactivity in anti S CLIA assay.

123


## 124 **Vaccine safety**

125 Figure 2 reports the frequency of all adverse events by type, cohort and severity.

126 A single intramuscular administration of GRAd-COV2 was well tolerated at all doses and in both  
127 cohorts. Overall, we observed 328 adverse events of any grade; of those, 255 were considered to  
128 be related with vaccination. In the younger age cohort we observed 143 solicited AEs (118 mild  
129 and 25 moderate) and 8 unsolicited AEs (4 mild and 4 moderate). In the older age cohort (we  
130 observed 104 solicited AEs (79 mild, 13 moderate and 2 severe) and 10 unsolicited AEs (5 mild,  
131 3 moderate and 2 severe). Twenty-four volunteers (26%; 7 younger and 17 older) reported no  
132 AE, 44 volunteers (48%; 23 younger and 21 older) reported at least one mild AE and 21  
133 volunteers (48%; 15 younger and 6 older) reported at least one moderate AE and 2 (2%; both  
134 older age volunteers) reported at least one severe adverse event. No serious AE was reported,  
135 and no pre-specified trial-halting rules were met. Nineteen volunteers (15 younger and 4 older)  
136 received antipyretics to control AEs. One older age volunteer received inhalator steroids for  
137 cough started the day after the vaccination that resolved in 9 days.

138 Most AEs occurred in the first 48 hours after vaccination and were short-lived (median time to  
139 resolution 24 hours, IQR less than 1 day-2 days).

140 Overall, no clinically significant blood count changes were observed. A transient reduction of  
141 neutrophils with concomitant increase in monocytes was detected at day 2 in the majority of  
142 volunteers in all age and vaccine dose groups that mostly reverted at pre-dose level by week 1  
143 (Fig S1). Other hematological parameters were mostly unaffected (Fig. S1, lymphocytes and  
144 platelets shown for reference), and no vaccine-related trends were noted for biochemistry  
145 parameters.



146

147 **Fig. 2. Adverse Event (AE) within 28 days after vaccination.** The proportion of volunteers in  
 148 each study arm experiencing the specific AE, and reported at the maximal severity, is shown.  
 149 The severity of AE is reported according to intensity scale in the protocol. (A) Younger adults

150 cohort. **(B)** Older adult cohort. Low: low-dose arm  $5 \times 10^{10}$  viral particles; Intermediate:  
151 intermediate-dose arm  $1 \times 10^{11}$  viral particles; High: high-dose arm  $2 \times 10^{10}$  viral particles.

152

### 153 **Binding antibodies to SARS-CoV-2 Spike**

154 Antibody response to GRAd-COV2 vaccination was primarily monitored by a clinically  
155 validated CLIA, revealing similar kinetics of anti-S IgG induction in all study groups (Fig. 3A  
156 and table S1). Seroconversion to S occurred at week 2, when anti-S IgG became detectable in 23  
157 (52%) out of 44 of the younger volunteers and in 15 (33%) out of 45 of the older age subjects. At  
158 week 4 after vaccination, high levels of anti-S IgG were measurable in 40 (91.0%) out of the 44  
159 analyzed younger and in 42 (93.3%) out of the 45 older age volunteers. In the younger age  
160 cohort, three volunteers (1 in ID and 2 in HD arm) showed a weak increase of anti-S-IgG (10.8  
161 AU/mL, 11.5 AU/mL and 12.8, respectively), that are below the diagnostic cutoff applied in the  
162 clinical practice (15.0 AU/mL). Only one volunteer in the LD arm showed anti-S-protein IgG  
163 below the assay limit of detection (LOD;  $<3.8$  AU/mL). Also in the older age cohort, three  
164 volunteers (1 in LD, 1 in ID, 1 in HD arm) showed a weak increase of anti-S-IgG (5.0 AU/mL,  
165 8.5 AU/mL and 9.7 respectively) that were below the diagnostic cutoff.

166 Antibodies measured by CLIA did not show a dose response relationship in the younger adult  
167 cohort (IgG levels at W4 were 59.5, 60.6 and 61.8 AU/mL for LD, ID and HD respectively,  
168  $P=0.742$ ). A dose response trend was observed in the older age cohort (IgG levels at W4 were  
169 31.8, 41.0 and 56.3 AU/mL for LD, ID and HD respectively,  $P=0.315$ ). However, despite the  
170 absence of a significant dose-response within the cohort, we observed that low and intermediate  
171 vaccine doses are associated to significantly lower IgG response in older age volunteers (LD  
172 arms median IgG was 59.4 in younger and 31.8 in older adults,  $P=0.011$ ; ID arms median IgG  
173 was 60.6 in younger and 41.0 in older adults,  $P=0.011$ ). Instead, high vaccine dose provided  
174 similar lever of IgG among the two age cohorts (high dose arms median IgG was 61.8 in younger  
175 and 56.3 in older adults,  $P=0.917$ ).

176 ELISA assay showed that 89 (98.8%) out of 90 volunteers developed detectable level of anti-S  
177 IgG (including both antibodies against the whole Spike protein and specific anti-RBD) at 4  
178 weeks after vaccination (Fig 3B-C and table S1).



179 Median titers to S and RBD showed a dose-response trend both in the younger and older age  
180 cohorts. We also observed that median level of IgG either against S or RBD were higher in  
181 younger than in older volunteers, although the difference between the two age cohorts were not  
182 significant (Fig. 3B-C and table S1).

183 None of the study volunteers showed seroconversion to N during the 4 weeks following  
184 vaccination, suggesting that no SARS-CoV-2 infection occurred.

185

### 186 **Neutralizing antibodies against SARS-CoV-2**


187 Neutralizing antibodies to SARS-CoV-2 were assessed by two different *in vitro* assays, both  
188 using SARS-CoV-2 live virus.

189 Microneutralization assay (MNA<sub>90</sub>) at week 4 after vaccination detected neutralizing antibodies  
190 in the serum of 25/44 (56.8%) young volunteers and 33/45 (73.3%) older age volunteers (Fig.  
191 3D). Anti-SARS-CoV-2 neutralizing antibodies were below the limit of detection in 8, 5 and 6  
192 younger, and in 3, 5 and 4 older volunteers in the LD, ID and HD arms, respectively.

193 Plaque reduction neutralization test (PRNT<sub>50</sub>) revealed that SARS-CoV-2 neutralizing antibodies  
194 were detectable in 42/44 (92.5%) younger and in 45/45 (100%) older age volunteers (Fig. 3E).  
195 The two younger volunteers with undetectable levels of neutralizing antibody were in the LD  
196 arm. We observed a significant increase of the level of neutralizing antibodies across the arms in  
197 the older adult cohort (median PRNT<sub>50</sub> titer 38.0, 35.0 and 61.0 in the LD, ID and HD arms  
198 respectively; P=0.048). A similar dose-response trend was also observed across the arms in the  
199 younger adults cohort (median PRNT<sub>50</sub> titer 23.5, 31.0 and 41.0 in the LD, ID and HD arms  
200 respectively; P=0.197).

201 Across all arms, titers of binding and neutralizing antibodies elicited by GRAd-COV2  
202 vaccination were in the range of those measured in subjects recovered from mild COVID-19  
203 (Fig. 3 A-D and table S1).

204



205  
206

207 **Fig. 3. SARS-CoV-2 specific binding and neutralizing antibody responses in GRAd-COV2**  
 208 **vaccinated volunteers.** Antibody response to SARS-CoV-2 induced by GRAd-COV2  
 209 vaccination at low dose (LD- $5 \times 10^{10}$  vp-circles), intermediate dose (ID- $1 \times 10^{11}$  vp-upright  
 210 triangles) and high dose (HD- $2 \times 10^{11}$  vp-upside down triangles). Blue and red color shades  
 211 identify younger and older age cohorts, respectively. Horizontal black lines are set at median  
 212 across all panels. HCS: human convalescent sera (diamonds), obtained from either previously  
 213 hospitalized (hosp-dark grey) or from non-hospitalized (non-hosp-light grey) COVID-19

214 patients, and the NIBSC 20/130 standard plasma (red diamond) are shown for reference. (A) IgG  
215 binding to S1-S2 measured by CLIA at day of vaccination (d0), and 1-2-4 weeks after  
216 vaccination. Data are expressed as arbitrary unit (AU)/ml. Blue and red dashed lines are set at 12  
217 and 15 AU/ml. According to manufacturer, results >15 are clearly positive, between 12 and 15  
218 are equivocal and <12 are negative or may indicate low level of IgG antibodies to the pathogen.  
219 (B-C) SARS-CoV-2 specific IgG titers in sera collected at d0 and w4 post vaccination measured  
220 by ELISA on recombinant full-length Spike (B) or RBD (C). Data are expressed as endpoint  
221 titer, and for negative sera where a titer cannot be calculated, an arbitrary value of 50 (or one-  
222 half the first serum dilution tested) is assigned. (D-E) SARS-CoV-2 neutralizing antibodies at  
223 week 4 post vaccination detected by SARS-CoV-2 microneutralization assay (D), or by plaque  
224 reduction neutralization test (E). SARS-CoV-2 neutralization titers are expressed as MNA<sub>90</sub> and  
225 PRNT<sub>50</sub>, or the reciprocal of serum dilution achieving 90% or 50% neutralization, respectively.  
226 Dashed lines indicate LOD, and negative sera are assigned a value of one/half the LOD.

227

## 228 **T cell response**

229 Quantitative IFN $\gamma$  ELISpot assay has been used to assess T cell response on freshly isolated  
230 PBMCs from volunteers in both cohorts at week 2 after vaccination.

231 GRAd-COV2 administration at all three doses induced potent S-specific IFN $\gamma$  producing T cell  
232 response in both cohorts (Fig. 4A and table S1). Individual responses ranged between 87 and  
233 10560 IFN $\gamma$  SFC/million PBMC in younger adults and between 283 and 18877 in older subjects.  
234 Notably, 80% of evaluable subjects across the two age cohorts showed a response above 1000  
235 SFC/million PBMC. Only one volunteer in arm1 did not show a detectable anti-S T cell response  
236 but still had measurable level of antibodies to S and RBD (ELISA titer of 1494 and 721  
237 respectively).


238 Figure 4 shows that an incremental level of T cell response was observed in younger (median  
239 response 1162, 2857 and 2272 SFC/per million PBMC in the LD, ID and HD arms, respectively;  
240 P=0.154) and older (median response 1917, 2262 and 3142 SFC in the LD, ID and HD arms,  
241 respectively, P=0.206) volunteers. However, neither trend was associated to a significant dose-  
242 response within the cohorts. Moreover, we did not find significant differences between younger

243 and older study arms receiving the same vaccine dose (P was 0.116, 0.0984 and 0.152 for LD, ID  
244 and HD, respectively).

245 T cell response induced by vaccination was directed to multiple epitopes, as most of the  
246 volunteers in both cohorts had a detectable response against all four S peptide pools analyzed  
247 (Fig. S2A and B). Moreover, we found that all regions of the S protein had a similar degree of  
248 immunogenicity in both age cohorts (Fig. 4B).

249 S-specific T cell response was generally higher in GRAd-COV2 vaccinated subjects than in  
250 SARS-CoV-2 convalescent controls who were sampled 1-2 months after symptoms onset.

251 Intracellular staining for cytokine production (ICS) and FACS analysis revealed that vaccine-  
252 induced responses involved both S protein specific CD4 and CD8 T lymphocytes in younger and  
253 older volunteers (Fig. 4C-D and E-F), with a slightly higher S-specific CD4 than CD8 T cell  
254 responses. Importantly, among GRAd-COV2 vaccine induced S-specific CD4, IFN $\gamma$  production  
255 was more prominent than IL4 and IL17 in both age cohorts, indicating that the vaccine induced a  
256 predominantly T helper 1 (Th1) response (tables below Fig. 4C and 4E report comparisons).



257

258 **Fig. 4. SARS-CoV-2 Spike specific T cell response in GRAd-COV2 vaccinated volunteers.** T

259 cell response to Spike peptides, induced by GRAd-COV2 vaccination at low (LD- $5 \times 10^{10}$  vp-

260 circles), intermediate dose (ID- $1 \times 10^{11}$  vp-upright triangles) and high dose (HD- $2 \times 10^{11}$  vp-upside

261 down triangles). Blue and red color shades identify younger and older age cohorts, respectively.  
262 Horizontal black lines are set at median across all panels. (A-B) IFN $\gamma$  ELISpot on freshly  
263 isolated PBMC at w2. Data are expressed as IFN- $\gamma$  spot forming cells (SFC)/10<sup>6</sup> PBMC. In (A)  
264 individual data points represent cumulative Spike T cell response, calculated by summing the  
265 response to each S1a, S1b, S2a and S2b peptide pools stimulation and correcting for background  
266 (DMSO stimulation) in each volunteer. HCP: freshly isolated human convalescent PBMC,  
267 obtained from subjects recovering from symptomatic SARS-CoV-2 infection. (B) distribution of  
268 IFN $\gamma$  ELISpot response to individual Spike peptide pools. Dashed line indicates assay positivity  
269 cut off (48 SFC/million PBMC). (C-D-E-F) IFN $\gamma$ /IL2/IL4/IL17 intracellular staining and FACS  
270 analysis at w2 on fresh PBMC of younger (C-D) and older volunteers (E-F). Data are expressed  
271 as the percentage of Spike-specific CD4 (C-E) or CD8 (D-F) secreting each cytokine (or for Any  
272 Th1 a combination of cytokines, i.e. sum of CD4 secreting IFN $\gamma$  alone, IL2 alone, and both IFN $\gamma$   
273 and IL2), obtained by summing responses to each of the 4 Spike peptide pools and corrected for  
274 background (DMSO stimulation). The tables below CD4 graphs shows P values derived by  
275 Kruskal-Wallis test comparing Th1/Th2/Th17 profile within each dose group.

276


### 277 **Anti-vector antibodies**

278 GRAd neutralization was not set as a screening or a randomization parameter, but was anyway  
279 assessed as an exploratory endpoint at baseline and 4 weeks after vaccination. Out of 90  
280 volunteers, we measured neutralization titers >200, a level above which an impact on vaccine  
281 immunogenicity has been reported, in only 10 volunteers (11%).

282 As expected, the vaccination with GRAd-COV2 induced or boosted anti-vector immunity in  
283 most volunteers (Fig. 5A), with no significant differences attributable to vaccine dose level or  
284 age.

285 To assess the impact of anti-GRAd immunity, pooled immunogenicity data at peak post  
286 vaccination (T, binding and neutralizing Ab responses) were stratified according to their baseline  
287 GRAd neutralizing titers (Fig. 5B-G). A trend for reduced S binding antibody response to the  
288 vaccine antigen was noted in volunteers with GRAd nAb >200 at baseline, with IgG titers  
289 measured by ELISA significantly lower (P=0.018 on full length S and P=0.0145 on RBD).

290 Similar trend was noted for T cell response and SARS-CoV-2 neutralizing Ab. Conversely,  
 291 vaccine-induced immune responses in individuals with GRAd nAb titers in the 18-200 range (i.e.  
 292 low but detectable) at baseline were undistinguishable or similar to those of volunteers with no  
 293 anti-vector immunity.



294


295 **Fig. 5. Neutralizing titers to GRAd before and after vaccination and impact on SARS-CoV-**  
296 **2 vaccine induced immune response.** (A) Neutralizing titers to GRAd vector measured in sera  
297 of vaccinated volunteers the day of vaccination (d0-filled symbols) and 4 weeks after (w4-open  
298 symbols). The dashed lines set at 18 indicate the assay LOD. The table reports the number (and  
299 percentage) of sera with GRAd nAb titer in the indicated range (<18, 18-200 or >=200) in  
300 younger, older, and overall across the two age cohorts of volunteers (N=90). (B-G) Volunteers  
301 are stratified according their GRAd nAb serostatus at baseline irrespective of age cohort and  
302 vaccine dose received, and for each stratum the vaccine-induced immune response is presented:  
303 the binding antibody response at w4 by CLIA S IgG (B), S ELISA (C), RBD ELISA (D); the  
304 SARS-CoV-2 neutralizing Ab response at w4 by MNA<sub>90</sub> (E), PRNT<sub>50</sub> (F); the T cell response by  
305 IFN $\gamma$  ELISpot at w2 (G).

306

### 307 **Correlative analysis of the immune response**

308 A correlation matrix was computed to define correlations between the immunological readouts of  
309 this study (Fig.6 and associated table). A strong positive correlation was observed among all  
310 serological tests (neutralization, CLIA, anti-S and anti-RBD ELISA). Correlation was strongest  
311 amongst assays detecting binding Abs (CLIA and ELISA to S and RBD, r values between 0.89  
312 and 0.94), and within the two neutralization assays (r=0.8). Correlation was significant but less  
313 strong within the two serology assay blocks (binding vs neutralizing, r between 0.5 and 0.66).  
314 Moreover, the T cell immunity significantly directly correlated with the serological assays  
315 (r=0.38 to 0.47), suggesting that GRAd-COV2 vaccination induces well-coordinated Ab and T  
316 cell responses to the encoded Spike. Of note and confirming the observation in previous  
317 paragraph, all vaccine induced immunological readouts trended to inversely correlate with the  
318 anti-vector antibody at baseline, reaching significance only for Ab responses as measured by  
319 ELISA (r= -0.24, P=0.026 for S, and r= -0.24 and P=0.024 for RBD).





	CLIA S	ELISA S	ELISA RBD	neut MNA	neut PRNT	neut GRAd d0	ELISpot
CLIA S		8.722e-031	2.177e-032	6.528e-008	8.0176e-007	0.263	3.036e-004
ELISA S	8.722e-031		2.614e-042	5.750e-012	1.8000e-010	0.026	3.637e-006
ELISA RBD	2.177e-032	2.614e-042		1.071e-011	3.2692e-010	0.024	1.688e-005
neut MNA	6.528e-008	5.750e-012	1.071e-011		1.2464e-020	0.059	7.201e-005
neut PRNT	8.018e-007	1.800e-010	3.269e-010	1.246e-020		0.121	2.672e-004
neut GRAd d0	0.263	0.026	0.024	0.059	0.1210		0.186
ELISpot	3.036e-004	3.637e-006	1.688e-005	7.201e-005	0.0003	0.186	

320

321

322 **Fig. 6. Correlation matrix of GRAd-COV2 immune response.** A correlation (non parametric  
 323 Spearman, two-tailed) matrix was computed for the full set of vaccinated volunteers irrespective  
 324 of and age cohort vaccine dose received, comparing the measured anti-SARS-CoV-2 or anti  
 325 vector immune response to evaluate how the different immune parameters correlate each other.  
 326 The analysis was run on 87/90 volunteers for which data for all assays were available. Spearman  
 327 r values are shown in the heatmap, and the table reports P values for each pair of variables.

328

## 329 DISCUSSION

330 Here we report the first-in-human data on the safety and immunogenicity of a single  
 331 administration of GRAd-COV2 given at different doses in healthy younger adults aged 18-55  
 332 and in healthy older adults aged 65-85 years. GRAd-COV2 is a COVID-19 candidate vaccine

333 based on a replication-defective gorilla adenovirus vector. Our analysis provides evidence that  
334 GRAd-COV2 is well tolerated in both younger and older age cohorts at all three doses assessed.  
335 Indeed at 4 week of follow-up most of the observed adverse events were short lived and mild or  
336 moderate in intensity. Only 2 volunteers reported at least one severe adverse event and none  
337 reported serious adverse events. Solicited adverse events were less common in older age  
338 volunteers, similarly to what described for other COVID-19 vaccines (5-7). In general, the  
339 adverse event profile did not differ from those reported in published work for other vector-based  
340 vaccines (7-12) while they were milder than those reported for mRNA formulated in  
341 liponanoparticles (LNP) and for adjuvanted vaccines (2, 13, 14).

342 The vaccine was immunogenic at all doses, inducing seroconversion in the majority of  
343 participants of both age groups. Onset of immune responses was rapid with T cell responses  
344 already detectable 14 days after vaccination and antibodies titers increasing to day 28. We used  
345 two assays to measure neutralizing antibodies against live SARS-CoV2 in vaccinated volunteers,  
346 which exploit different virus strains and readouts. A microneutralization assay based on  
347 cytopathic effect (CPE) assessment provided evidence that 65% of the volunteers had  
348 measurable MNA<sub>90</sub> titers, while a more sensitive plaque reduction assay could determine  
349 PRNT<sub>50</sub> titers a in 98% of vaccinated volunteers. In general, titers of neutralizing antibodies to  
350 SARS-CoV-2 were lower than those reported in studies of vaccines based on mRNA (13, 15, 16)  
351 and on other viral vectors like Ad26 and ChAdOx1(7, 9). However, the lack of standards and use  
352 of different assays complicate the comparison of performance of the various COVID-19 vaccines  
353 that are currently in use or in development. A comparison with convalescent serum panels  
354 stratified according to COVID-19 severity of the donors, showed that volunteers who received  
355 the GRAd-COV2 vaccine elicited similar titers of SARS-CoV-2 binding and neutralizing  
356 antibodies as did non-hospitalized people who had recovered from symptomatic COVID-19. In  
357 addition, the proportion of volunteers with detectable levels of neutralizing antibodies 28 days  
358 after vaccination seems not inferior to that reported in clinical studies after a single  
359 administration of other vaccines, including BNT162b2 (5, 16), mRNA-1273 (13, 17), Gam-  
360 COVID-Vac (10), ChAdOx-1 (8, 9), Ad-26 (7) and Ad5-vectored COVID-19 (11, 12),  
361 suggesting that the measured lower nAb titers could result from different assay sensitivities.

362 There is a lack of knowledge on reliable immune correlates that would predict the efficacy of  
363 COVID-19 vaccines (18-20). However, preliminary evidence from a non-human primate model  
364 (21), clinical observation of the natural infection (22) as well as evidence of protective efficacy  
365 after first dose for several authorized vaccines (5, 17, 23) suggested that even low titer of  
366 neutralizing titers may be protective. The single administration of GRAd-COV2 elicits robust  
367 and Th1-skewed immune response, similar to that induced by a single dose of other vectored  
368 COVID-19 vaccines such as ChAdOx1 nCoV-19 (8, 9), Ad5 (11, 12) and Ad26 (7), and by two  
369 doses of mRNA-1273 (13, 15). Indeed, a single administration of GRAd-COV2 elicits, within 2  
370 weeks, a Th1 immune response that is broadly directed to multiple S protein epitopes.  
371 Importantly, a robust T cell response, such as that elicited by GRAd-COV-2, likely determines  
372 the duration of anti-COVID-19 immunity (24, 25) and prevents unintended immune reactions  
373 such as the vaccine-associated enhanced respiratory disease (VAERD) (26, 27). Moreover, S  
374 protein-specific T cell responses directly correlated with binding and neutralizing antibodies,  
375 suggesting that GRAd-COV2 vaccine is able to shape a well-balanced and coordinated cellular  
376 and humoral specific immune response, as this naturally occurs in mild COVID-19 (28, 29).

377 New SARS-CoV-2 variants are becoming predominant through a process of evolutionary  
378 selection that is not well understood. Among others, a variant of concern is the B.1.351 strain  
379 which is less effectively neutralized by convalescent plasma from COVID-19 patients and by  
380 sera from those vaccinated with several vaccines in development (30-32). The decrement in  
381 neutralization can be more than 10-fold with convalescent plasma and averages 5- to 6-fold less  
382 with sera from vaccinated individuals. The interim data from a randomized placebo-controlled  
383 vaccine study, of rAd26 from Janssen in the US, Brazil, and South Africa showed efficacy  
384 against COVID-19 at 72%, 66%, and 57%, respectively (<https://www.jnj.com/johnson-johnson-announcingsingle-shot-janssen-covid-19-vaccine-candidatemet-primary-endpoints-in-interim-analysis-of-itsphase-3-ensemble-trial>). Viral sequence data from infected patients showed that  
387 the B.1.351 strain was responsible for the majority of infections in South Africa. Lower vaccine  
388 efficacy in the South Africa cohort could be related to antigenic variation or to geographic or  
389 population differences. Interestingly, despite the reduced efficacy, the single dose of rAd26  
390 vaccine was 85% effective overall in preventing severe COVID-19, and protection was similar in  
391 all regions. Given the important reduction of neutralizing activity on the B.1.351 variant, it is

392 tempting to speculate that the vaccine-induced T cell responses might be predominant in  
393 protecting from severe disease.

394 As for other candidate vaccines using viral vectors, pre-existing immune responses against the  
395 vector can compromise the induction of an immune response against the target antigen (33, 34)  
396 and indeed this was shown also for a candidate COVID-19 vaccine based on the common human  
397 Ad5 serotype (11). In our study, high levels of neutralizing antibodies against GRAd-COV2  
398 were associated with a reduced median T cell response and antibody levels against S protein.  
399 Albeit significant, the presence of pre-existing anti-GRAd antibodies did not abrogate the  
400 immune response in most of the volunteers. These findings highlight the potential utility of  
401 vectors such as GRAd, for which pre-existing immunity is infrequent in the human population.

402 Our interim analysis indicates that vaccine candidate GRAd-COV2 is safe and immunogenic in  
403 both younger and older adults. This finding has supported and guided our decision to proceed  
404 with an ongoing phase 2/3 trial (NCT04791423) to evaluate the efficacy of either a single dose or  
405 of a two-dose regimen of GRAd-COV2.

406 Indeed, experience from other ongoing clinical trials on adenovirus-based vaccines provided  
407 evidence that a second administration of vaccine is safe and can significantly improve the  
408 production of neutralizing antibodies (9, 10). The observed increase of anti-GRAd neutralizing  
409 antibody titers post vaccination is in line with that observed with other adenovirus based  
410 COVID-19 vaccines (6, 7) which did not prevent boosting of anti-S antibodies upon a second  
411 administration. It is worth noticing that most of the anti-COVID-19 vaccines need a prime boost  
412 scheme, including non-replicating viral vectored vaccines, mRNA and adjuvanted subunit  
413 vaccines.

414 This study has some limitations due to the low number of volunteers per arm (N=15), and to the  
415 lack of subject randomization amongst study arms on the basis of GRAd neutralizing titer at  
416 baseline. Both these aspects could have had an impact in the poor vaccine dose effect observed.  
417 However, the explored dose range (4-fold between low and high dose) was limited, and no major  
418 dose effect was expected. Nevertheless, for phase 2/3 single-dose regimen we selected the  $2 \times 10^{11}$   
419 vp (high) dose, due to higher and more consistent immunogenicity especially in the elderly  
420 cohort. As for the two-dose regimen, the intermediate dose of  $1 \times 10^{11}$  vp was selected which  
421 represents the best compromise between tolerability and immunogenicity. Finally, data beyond

422 w4 post vaccination on persistence of humoral and cellular responses will be part of a future  
423 report once the study follow up will be completed.

424

## 425 **MATERIALS AND METHODS**

### 426 **Study design**

427 This study is a phase 1, dose-escalation, open label clinical trial designed to determine the safety  
428 and immunogenicity of GRAd-COV2. The study included two age cohorts, of either younger  
429 (18-55) or older (65-85) adults. Each cohort consisted of 3 arms of 15 volunteers each, for  
430 assessing a single administration at three different dose levels of GRAd-COV2: low dose (LD)  
431  $5 \times 10^{10}$ ; intermediate dose (ID)  $1 \times 10^{11}$  and high dose (HD)  $2 \times 10^{11}$  viral particles (vp). We report  
432 here the safety and immunogenicity endpoints collected in the first 4 weeks after vaccination for  
433 the volunteers enrolled in both age cohorts, as foreseen in the study Protocol (Interim analyses 1  
434 and 2). The full study protocol is provided in Supplementary material.

435 **Volunteers and settings:** eligible participants were healthy adults aged 18 to 55 years with no  
436 history of COVID-19, no laboratory findings suggestive of current or previous infection with  
437 SARS-COV-2 and who have attended the screening visit no more than 21 days before  
438 vaccination (appendix 1 lists all eligibility criteria).

439 **Trial procedures:** GRAd-COV2 was manufactured by ReiThera under good manufacturing  
440 practice conditions, suspended in formulation buffer at a concentration of  $2 \times 10^{11}$  vp/mL.  
441 Volunteers received a single intramuscular injection in the deltoid. For administration of the HD,  
442 1ml of GRAd-COV2 was injected without dilution. For ID and LD, the vaccine was diluted in  
443 sterile saline solution to reach a final 1ml injection volume.

444 The dose-escalation staggered enrollment included 3 sentinel volunteers in the LD arm followed  
445 by enrollment of the full LD arm. ID and HD sentinel volunteers were enrolled 7 days after that  
446 safety data of LD or ID arm were available, respectively. All the enrollment, stages were  
447 supervised by an independent data safety monitoring board. Volunteers recorded local and  
448 systemic reactions on a diary card for 28 days. The severity and relatedness with vaccination or  
449 adverse events were assessed by the medical team in each center.

### 450 **Specimens from SARS-COV-2 convalescent patients**

451 As comparator for immunogenicity analysis we used three independent sets of anonymized  
452 specimens (sera and PBMC) from COVID-19 patients either hospitalized or recovering from  
453 mild symptomatic disease, collected 20 to 60 days after symptom onset. The Research reagent  
454 for anti-SARS-CoV-2 Ab (NIBSC code 20/130), a human plasma from a donor recovered from  
455 COVID-19, was included as a positive control.

#### 456 **Ethical statement**

457 All participants provided written informed consent before enrolment. The trial was conducted at  
458 the National Institute for Infectious Diseases Lazzaro Spallanzani (INMI) in Rome and at Centro  
459 Ricerche Cliniche in Verona (CRC-Verona). The study was conducted according to the  
460 Declaration of Helsinki, and approved by the Italian Regulatory Drug Agency (AIFA) and the  
461 Italian National Ethical Committee for COVID-19 clinical studies (ClinicalTrials.gov  
462 NCT04528641; EudraCT 2020-002835-31).

463 Sera from convalescent patients who resolved SARS-CoV-2 infections came from residual  
464 specimens used for diagnostic purposes and were utilized according to INMI protocols for  
465 observational studies approved form internal ethical committee.

#### 466 **SARS-CoV-2 anti-Spike and anti-Nucleoprotein IgG high throughput Chemiluminescence** 467 **Immunoassay**

468 Two commercial Ig assays were used according to manufacturer's protocols: 1) DiaSorin  
469 LIAISON® SARS-CoV-2 S1/S2 IgG test on LIAISON® XL analyzers, a chemiluminescence  
470 immunoassays (CLIA) detecting anti-S1/S2 IgG (IgG antibody concentrations expressed as  
471 arbitrary units, AU/mL  $\geq 15$  are considered positive, DiaSorin, Italy); 2) Abbott SARS-CoV-2  
472 assay on Abbott ARCHITECT® i2000sr, a chemiluminescence microparticle assay (CMIA)  
473 detecting anti-N IgG (index value Sample/Cut-off  $\geq 1.4$  is considered positive; Abbott  
474 Diagnostics, Chicago, IL, USA). The laboratory turnaround/determination is of 30 minutes for  
475 both CLIA and CMIA.

#### 476 **SARS-CoV-2 Spike and RBD ELISA**

477 SARS-CoV-2 ELISA was developed using as coated antigens either SARS-CoV-2 full length  
478 soluble prefusion stabilized Spike protein (expressed in Expi293 cells at ReiThera) or a  
479 recombinant RBD (expressed in HEK293 cells, ACROBiosystems). Proteins were coated on

480 NUNC Maxisorp plates (ThermoFisher Scientific) at optimized concentration (5 µg/ml for R121,  
481 2,5 µg/ml for RBD) in PBS overnight at 4°C. The following day, plates were washed with PBS  
482 0,05% Tween-20 (PBS-T), then blocked with PBS-T+3% non-fat dry milk for 1,5h at 25°C in  
483 shaking. After wash, serum dilution curves (six 3-fold serial dilution of human sera from 1:100  
484 to 1:24,300) prepared in PBS-T+1% non-fat dried milk were plated and incubated for 2h at 25°C  
485 in shaking. Plates were then washed and incubated with 1:2000 diluted anti-human IgG (Fc-  
486 specific, Sigma) for 1h at 25°C in shaking. Plates were then washed one last time and incubated  
487 with alkaline phosphatase substrate SigmaFast (Sigma) at 25°C. Absorbance was read at 405  
488 and 620 nm using EnSight multiple plate reader (PerkinElmer), at 10, 20 and 30 minutes; the  
489 read with the best R-squared value was used to calculate endpoint titers. The endpoint titer was  
490 defined as the highest serum dilution that resulted in an absorbance value (OD-optical density)  
491 just above the calculated background of 4-fold the OD from secondary antibody alone. A  
492 COVID-19 convalescent patient's serum at 1:200 and 1:6400 dilution was included as positive  
493 control in each plate to ensure inter-assay reproducibility. The research reagent for anti-SARS-  
494 CoV-2 Ab NIBSC code 20/130 was used as standard reference in each experiment.

#### 495 **SARS-CoV-2 microneutralization assay (MNA)**

496 Sera collected from vaccinated volunteer or convalescent COVID-19 patients were heat-  
497 inactivated at 56°C for 30 minutes (min), and titrated in duplicate in 7 two-fold serial dilutions  
498 (starting dilution 1:10). Equal volumes of 100 TCID<sub>50</sub> SARS-CoV-2 (strain 2019-nCoV/Italy-  
499 INMI1; GISAID accession ID: EPI\_ISL\_412974) and serum dilutions, were mixed and  
500 incubated at 37 °C 5% CO<sub>2</sub> for 30 min. Subsequently, 96-well tissue culture plates with sub-  
501 confluent Vero E6 cell monolayers were infected with 100 µl/well of virus-serum mixtures and  
502 incubated at 37 °C and 5% CO<sub>2</sub>. To standardize inter-assay procedures, positive control samples  
503 showing high (1:160) and low (1:40) neutralizing activity were included in each MNA session.  
504 After 48 hours, microplates were observed by light microscope for the presence of CPE. The  
505 supernatant of each plate was carefully discarded and 120 µl of a Crystal Violet solution  
506 containing 2% Formaldehyde was added to each well. After 30 min, the fixing solution was  
507 removed by washing with tap water and cell viability measured by photometer at 595 nm  
508 (Synergy™ HTX Multi-Mode Microplate Reader, Biotek). The highest serum dilution inhibiting  
509 at least 90% of the CPE was indicated as the neutralization titre and expressed as the reciprocal

510 of serum dilution (MNA<sub>90</sub>). Serum from the National Institute for Biological Standards and  
511 Control, UK (NIBSC) with known neutralization titer was used as reference in MNA (Research  
512 reagent for anti-SARS-CoV-2 Ab NIBSC code 20/130).

### 513 **SARS-CoV-2 plaque reduction neutralization test (PRNT)**

514 As an exploratory endpoint, the SARS-CoV-2 PRNT<sub>50</sub> titers of vaccinated volunteers' sera was  
515 determined by means of a plaque reduction neutralization test (PRNT) developed and run at  
516 Viroclinics Biosciences. Briefly, a standard number of SARS-CoV-2 (Bav/Pat1/2020 strain)  
517 infectious units were incubated with eight two-fold serial dilutions of heat inactivated sera,  
518 starting from 1:8 and up to 1:1024. After 1h pre-incubation, the virus/serum mixtures were  
519 inoculated on VeroE6 cells for 1 hour, than washed, replaced with infection medium and the  
520 cells were left overnight. After 16-24h the cells were formalin-fixed, permeabilized with ethanol,  
521 and incubated with primary anti SARS-CoV-2 Nucleocapsid monoclonal antibody followed by a  
522 secondary anti-mouse IgG peroxidase conjugate and TrueBlue substrate, which forms a blue  
523 precipitate on positive cells. Images of all wells were acquired by an ImmunoSpot analyzer  
524 (Cellular Technology Limited-CTL), equipped with software capable to accurately count the  
525 virus positive cells. The 50% neutralization titers were calculated according to a method  
526 described earlier (35). The NIBSC standard 20/130 was tested as reference in the same run than  
527 the RT-COV-2 trial serum samples, with resulting PRNT<sub>50</sub> of 697 and 934 for younger and older  
528 adults assay runs, respectively.

### 529 **GRAd Neutralizing Antibody Assay**

530 Neutralizing antibody (nAb) titers in human sera were assayed as previously described (36).  
531 Briefly,  $8 \times 10^4$  HEK293 cells per well were seeded in 96 well plates the day before the assay.  
532 GRAd vector encoding for the reporter gene secreted alkaline phosphatase (SEAP) at a pre-  
533 optimized multiplicity of infection (MOI) was preincubated for 1h at 37°C alone or with serial  
534 dilutions of control or test serum samples and then added to the 80-90% confluent HEK293 cells.  
535 After incubation for 1h at 37°C, the serum/infection mix was removed and replaced with 10%  
536 FBS in DMEM. SEAP expression was measured 24 hours later in cell supernatant by means of  
537 the chemiluminescent substrate from the Phospha-Light™ kit (Applied Biosystems).  
538 Neutralization titers were defined as the dilution at which a 50% reduction of SEAP activity  
539 from serum sample was observed relative to SEAP activity from virus alone.



## 540 **PBMC isolation and stimulation**

541 Peripheral venous blood (40 ml) was collected in 7 ml lithium-heparin Vacutest blood collection  
542 tubes (Kima). Peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood  
543 by density gradient centrifugation (Histopaque 1077, Sigma Aldrich). After separation, PBMC  
544 were suspended in RPMI 1640 (Sigma Aldrich) supplemented with 10% heat-inactivated highly  
545 defined fetal bovine serum (FBS) (HyClone), 2 mmol/L L-glutamine, 10 mmol/L HEPES buffer  
546 (N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid, Sigma Aldrich), and 100 U/ml penicillin,  
547 and 100 µg/ml streptomycin (Gibco), hereafter termed R10. PBMC count and viability were  
548 performed by using Guava Muse (Luminex). A set of 316 15mer peptides overlapping by 11  
549 amino acids (synthesized by Elabscience Biotech Inc, and distributed by TEMA RICERCA),  
550 designed to cover the full-length S protein, was arranged into 4 pools (S1a, S1b-including RBD  
551 domain, S2a and S2b). PBMC ( $2 \times 10^6$ /ml) were stimulated with the four Spike peptides pools for  
552 18 hours (3µg/ml each peptide final concentration). For flow-cytometry experiments, brefeldin A  
553 (10ug/ml, Sigma Aldrich) was added to block endoplasmic reticulum and Golgi apparatus.

## 554 **IFN $\gamma$ ELISpot assay**

555 The frequency of IFN $\gamma$ -producing T cells was assessed by enzyme-linked immunosorbent spot-  
556 forming cell assay (ELISpot) after specific stimulation. PBMCs were resuspended in R10,  
557 stimulated with peptides pools, as described above, and plated at  $2 \times 10^5$  cells/well in ELISpot  
558 plates (Human IFN- $\gamma$  ELISpot plus kit; Mabtech). PBMCs were incubated for 18-20 hours with  
559 5% of CO<sub>2</sub>. At the end of incubation, the ELISpot assay was developed according to  
560 manufacturer's instructions. Spontaneous cytokine production (background) was assessed by  
561 incubating PBMC with DMSO, the peptides diluent (Sigma,). Results are expressed as spot  
562 forming cells (SFC)/ $10^6$  PBMCs in stimulating cultures after subtracting spontaneous  
563 background. A result was considered positive if matching two criteria: i) higher than >48  
564 SFC/ $10^6$  PBMC and ii) higher than 3 times Background. Data from three volunteers were  
565 excluded from all ELISpot analyses since their spontaneous IFN $\gamma$  secretion in DMSO wells  
566 (yLD-101027, 450 SFC; yID-101034, 465 SFC; oID-101072, 233 SFC on DMSO) was above  
567 the mean+2standard deviation of the study population (mean=42 SFC, SD=72.27,  
568 mean+2SD=186 SFC/million PBMC), leading to unreliable quantitative analysis.

## 569 **Intracellular staining and flow-cytometry**

570 Intracellular flow cytometry was performed by using ViaKrome 808 Fixable Viability dye, anti-  
571 IL17a Alexa Fluor 700, anti-CD45 Krome Orange, (Beckman Coulter), anti-CD3 BUV661, anti-  
572 CD8 PercP, anti-CD4 V450, anti-IL2 FITC, anti-IL4 PE (BD Biosciences), and anti-IFN- $\gamma$  PE-  
573 Vio770 (Milteny Biotec). Briefly, PBMC were washed in DPBS (Corning) and stained with  
574 ViaKrome 808 Fixable Viability dye, anti-CD45, anti-CD3, anti-CD8, anti-CD4 for 15 minutes  
575 at 4°C. After washing cells were fixed with PFA 1% (Electron Microscopy Science), then  
576 stained with anti-IL17a, anti-IL2, anti-IL4 and anti-IFN- $\gamma$  in PBS (Corning) BSA 0.5% (Sigma  
577 Aldrich) and Sodium Azide 0.01% (Serva Serving Scientists), saponin 0.5% (Sigma Aldrich) for  
578 30 minutes at room temperature. Acquisition of 200,000 events was performed in the CD3+  
579 gated population on CytoFLEX LX flow-cytometer, and analyzed with CytExpert software  
580 (Beckman Coulter). Data were analyzed with CytExpert software (Beckman Coulter: doublets  
581 were excluded in the FSC-H/FSC-A dot plot. Live cells were selected as Viakrome neg cells. In  
582 the immunological plot (SideScatter (SSC)/CD45), the CD45+ cells were gated, followed by  
583 gating CD3+ lymphocytes. Among the CD3+ cells, CD4+ or CD8+ cells were selected and the  
584 percentage CD4 or CD8 cells producing cytokines were evaluated. Spontaneous cytokines  
585 production (DMSO stimulation) was subtracted.

## 586 **Statistical analysis**

587 This is a descriptive phase I first in human trial to assess safety and immunogenicity of three  
588 different vaccine doses and no formal sample size calculation is carried out. Categorical  
589 variables including occurrence of adverse events (AE) and detectable levels of binding and  
590 neutralizing antibody against SARS-CoV-2 and GRAd were reported as proportions. Continuous  
591 variables including results of CLIA anti-S IgG, MNA<sub>90</sub> titers, PNRT<sub>50</sub> titers and ELISpot values  
592 for IFN $\gamma$  secretion were reported as median and interquartile range. Comparison of medians  
593 across arms and the impact of pre-existing immunity against GRAd were evaluated by two-tailed  
594 Kruskal–Wallis one-way variance analysis. Association between categorical variable was carried  
595 out by Fisher exact test. Correlations between immunogenicity assays were assessed by non-  
596 parametric Spearman's rank tests.

## 597 **Supplementary Materials**

598 Fig. S1. Hematological parameters over time.

599 Fig. S2. Breadth of GRAd-COV-2 induced T cell response.

600 Table S1. Median and Interquartile range of main immunological measures.

601 RT-CoV-2 study Protocol

602

## 603 References and Notes

- 604 1. L. Dai, G. F. Gao, Viral targets for vaccines against COVID-19. *Nat Rev Immunol* **21**, 73-  
605 82 (2021).
- 606 2. J. Pallesen, N. Wang, K. S. Corbett, D. Wrapp, R. N. Kirchdoerfer, H. L. Turner, C. A.  
607 Cottrell, M. M. Becker, L. Wang, W. Shi, W. P. Kong, E. L. Andres, A. N. Kettenbach,  
608 M. R. Denison, J. D. Chappell, B. S. Graham, A. B. Ward, J. S. McLellan,  
609 Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike  
610 antigen. *Proc Natl Acad Sci U S A* **114**, E7348-E7357 (2017).
- 611 3. D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C. L. Hsieh, O. Abiona, B. S.  
612 Graham, J. S. McLellan, Cryo-EM structure of the 2019-nCoV spike in the prefusion  
613 conformation. *Science* **367**, 1260-1263 (2020).
- 614 4. S. Capone, A. Raggioli, M. Gentile, S. Battella, A. Lahm, A. Sommella, A. M. Contino,  
615 R. A. Urbanowicz, R. Scala, F. Barra, A. Leuzzi, E. Lilli, G. Miselli, A. Noto, M.  
616 Ferraiuolo, F. Talotta, T. Tsoleridis, C. Castilletti, G. Matusali, F. Colavita, D. Lapa, S.  
617 Meschi, M. Capobianchi, M. Soriani, A. Folgori, J. K. Ball, S. Colloca, A. Vitelli,  
618 Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19. *bioRxiv*,  
619 2020.2010.2022.349951 (2020).
- 620 5. F. P. Polack, S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez,  
621 G. Perez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S. Roychoudhury,  
622 K. Koury, P. Li, W. V. Kalina, D. Cooper, R. W. Frenck, Jr., L. L. Hammitt, O. Tureci,  
623 H. Nell, A. Schaefer, S. Unal, D. B. Tresnan, S. Mather, P. R. Dormitzer, U. Sahin, K. U.  
624 Jansen, W. C. Gruber, C. C. T. Group, Safety and Efficacy of the BNT162b2 mRNA  
625 Covid-19 Vaccine. *N Engl J Med* **383**, 2603-2615 (2020).
- 626 6. M. N. Ramasamy, A. M. Minassian, K. J. Ewer, A. L. Flaxman, P. M. Folegatti, D. R.  
627 Owens, M. Voysey, P. K. Aley, B. Angus, G. Babbage, S. Belij-Rammerstorfer, L. Berry,  
628 S. Bibi, M. Bittaye, K. Cathie, H. Chappell, S. Charlton, P. Cicconi, E. A. Clutterbuck, R.  
629 Colin-Jones, C. Dold, K. R. W. Emary, S. Fedosyuk, M. Fuskova, D. Gbesemete, C.  
630 Green, B. Hallis, M. M. Hou, D. Jenkin, C. C. D. Joe, E. J. Kelly, S. Kerridge, A. M.  
631 Lawrie, A. Lelliott, M. N. Lwin, R. Makinson, N. G. Marchevsky, Y. Mujadidi, A. P. S.  
632 Munro, M. Pacurar, E. Plested, J. Rand, T. Rawlinson, S. Rhead, H. Robinson, A. J.  
633 Ritchie, A. L. Ross-Russell, S. Saich, N. Singh, C. C. Smith, M. D. Snape, R. Song, R.  
634 Tarrant, Y. Themistocleous, K. M. Thomas, T. L. Villafana, S. C. Warren, M. E. E.  
635 Watson, A. D. Douglas, A. V. S. Hill, T. Lambe, S. C. Gilbert, S. N. Faust, A. J. Pollard,  
636 C. V. T. G. Oxford, Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine  
637 administered in a prime-boost regimen in young and old adults (COV002): a single-blind,  
638 randomised, controlled, phase 2/3 trial. *Lancet* **396**, 1979-1993 (2021).

- 639 7. J. Sadoff, M. Le Gars, G. Shukarev, D. Heerwegh, C. Truyers, A. M. de Groot, J. Stoop,  
640 S. Tete, W. Van Damme, I. Leroux-Roels, P. J. Berghmans, M. Kimmel, P. Van Damme,  
641 J. de Hoon, W. Smith, K. E. Stephenson, S. C. De Rosa, K. W. Cohen, M. J. McElrath, E.  
642 Cormier, G. Scheper, D. H. Barouch, J. Hendriks, F. Struyf, M. Douoguih, J. Van Hoof,  
643 H. Schuitemaker, Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19  
644 Vaccine. *N Engl J Med*, (2021).
- 645 8. P. M. Folegatti, M. Bittaye, A. Flaxman, F. R. Lopez, D. Bellamy, A. Kupke, C. Mair, R.  
646 Makinson, J. Sheridan, C. Rohde, S. Halwe, Y. Jeong, Y. S. Park, J. O. Kim, M. Song, A.  
647 Boyd, N. Tran, D. Silman, I. Poulton, M. Dato, J. Marshall, Y. Themistocleous, A.  
648 Lawrie, R. Roberts, E. Berrie, S. Becker, T. Lambe, A. Hill, K. Ewer, S. Gilbert, Safety  
649 and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-  
650 vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1  
651 trial. *Lancet Infect Dis* **20**, 816-826 (2020).
- 652 9. P. M. Folegatti, K. J. Ewer, P. K. Aley, B. Angus, S. Becker, S. Belij-Rammerstorfer, D.  
653 Bellamy, S. Bibi, M. Bittaye, E. A. Clutterbuck, C. Dold, S. N. Faust, A. Finn, A. L.  
654 Flaxman, B. Hallis, P. Heath, D. Jenkin, R. Lazarus, R. Makinson, A. M. Minassian, K.  
655 M. Pollock, M. Ramasamy, H. Robinson, M. Snape, R. Tarrant, M. Voysey, C. Green, A.  
656 D. Douglas, A. V. S. Hill, T. Lambe, S. C. Gilbert, A. J. Pollard, C. V. T. G. Oxford,  
657 Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a  
658 preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet* **396**,  
659 467-478 (2020).
- 660 10. D. Y. Logunov, I. V. Dolzhikova, O. V. Zubkova, A. I. Tukhvatulin, D. V.  
661 Shcheblyakov, A. S. Dzharullaeva, D. M. Grousova, A. S. Erokhova, A. V. Kovyrshina,  
662 A. G. Botikov, F. M. Izhaeva, O. Popova, T. A. Ozharovskaya, I. B. Esmagambetov, I. A.  
663 Favorskaya, D. I. Zrelkin, D. V. Voronina, D. N. Shcherbinin, A. S. Semikhin, Y. V.  
664 Simakova, E. A. Tokarskaya, N. L. Lubenets, D. A. Egorova, M. M. Shmarov, N. A.  
665 Nikitenko, L. F. Morozova, E. A. Smolyarchuk, E. V. Kryukov, V. F. Babira, S. V.  
666 Borisevich, B. S. Naroditsky, A. L. Gintsburg, Safety and immunogenicity of an rAd26  
667 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two  
668 formulations: two open, non-randomised phase 1/2 studies from Russia. *Lancet* **396**, 887-  
669 897 (2020).
- 670 11. F. C. Zhu, X. H. Guan, Y. H. Li, J. Y. Huang, T. Jiang, L. H. Hou, J. X. Li, B. F. Yang,  
671 L. Wang, W. J. Wang, S. P. Wu, Z. Wang, X. H. Wu, J. J. Xu, Z. Zhang, S. Y. Jia, B. S.  
672 Wang, Y. Hu, J. J. Liu, J. Zhang, X. A. Qian, Q. Li, H. X. Pan, H. D. Jiang, P. Deng, J. B.  
673 Gou, X. W. Wang, X. H. Wang, W. Chen, Immunogenicity and safety of a recombinant  
674 adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a  
675 randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet* **396**, 479-488 (2020).
- 676 12. F. C. Zhu, Y. H. Li, X. H. Guan, L. H. Hou, W. J. Wang, J. X. Li, S. P. Wu, B. S. Wang,  
677 Z. Wang, L. Wang, S. Y. Jia, H. D. Jiang, L. Wang, T. Jiang, Y. Hu, J. B. Gou, S. B. Xu,  
678 J. J. Xu, X. W. Wang, W. Wang, W. Chen, Safety, tolerability, and immunogenicity of a  
679 recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-  
680 label, non-randomised, first-in-human trial. *Lancet* **395**, 1845-1854 (2020).
- 681 13. L. A. Jackson, E. J. Anderson, N. G. Roupheal, P. C. Roberts, M. Makhene, R. N. Coler,  
682 M. P. McCullough, J. D. Chappell, M. R. Denison, L. J. Stevens, A. J. Pruijssers, A.  
683 McDermott, B. Flach, N. A. Doria-Rose, K. S. Corbett, K. M. Morabito, S. O'Dell, S. D.  
684 Schmidt, P. A. Swanson, 2nd, M. Padilla, J. R. Mascola, K. M. Neuzil, H. Bennett, W.

- 685 Sun, E. Peters, M. Makowski, J. Albert, K. Cross, W. Buchanan, R. Pikaart-Tautges, J. E.  
686 Ledgerwood, B. S. Graham, J. H. Beigel, R. N. A. S. G. m, An mRNA Vaccine against  
687 SARS-CoV-2 - Preliminary Report. *N Engl J Med* **383**, 1920-1931 (2020).
- 688 14. C. Keech, G. Albert, I. Cho, A. Robertson, P. Reed, S. Neal, J. S. Plested, M. Zhu, S.  
689 Cloney-Clark, H. Zhou, G. Smith, N. Patel, M. B. Frieman, R. E. Haupt, J. Logue, M.  
690 McGrath, S. Weston, P. A. Piedra, C. Desai, K. Callahan, M. Lewis, P. Price-Abbott, N.  
691 Formica, V. Shinde, L. Fries, J. D. Lickliter, P. Griffin, B. Wilkinson, G. M. Glenn,  
692 Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. *N*  
693 *Engl J Med* **383**, 2320-2332 (2020).
- 694 15. E. J. Anderson, N. G. Roupael, A. T. Widge, L. A. Jackson, P. C. Roberts, M. Makhene,  
695 J. D. Chappell, M. R. Denison, L. J. Stevens, A. J. Pruijssers, A. B. McDermott, B. Flach,  
696 B. C. Lin, N. A. Doria-Rose, S. O'Dell, S. D. Schmidt, K. S. Corbett, P. A. Swanson, 2nd,  
697 M. Padilla, K. M. Neuzil, H. Bennett, B. Leav, M. Makowski, J. Albert, K. Cross, V. V.  
698 Edara, K. Floyd, M. S. Suthar, D. R. Martinez, R. Baric, W. Buchanan, C. J. Luke, V. K.  
699 Phadke, C. A. Rostad, J. E. Ledgerwood, B. S. Graham, J. H. Beigel, R. N. A. S. G. m,  
700 Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *N*  
701 *Engl J Med* **383**, 2427-2438 (2020).
- 702 16. E. E. Walsh, R. W. Frenck, Jr., A. R. Falsey, N. Kitchin, J. Absalon, A. Gurtman, S.  
703 Lockhart, K. Neuzil, M. J. Mulligan, R. Bailey, K. A. Swanson, P. Li, K. Koury, W.  
704 Kalina, D. Cooper, C. Fontes-Garfias, P. Y. Shi, O. Tureci, K. R. Tompkins, K. E. Lyke,  
705 V. Raabe, P. R. Dormitzer, K. U. Jansen, U. Sahin, W. C. Gruber, Safety and  
706 Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *N Engl J Med* **383**,  
707 2439-2450 (2020).
- 708 17. L. R. Baden, H. M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S. A.  
709 Spector, N. Roupael, C. B. Creech, J. McGettigan, S. Khetan, N. Segall, J. Solis, A.  
710 Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M.  
711 Marovich, J. Mascola, L. Polakowski, J. Ledgerwood, B. S. Graham, H. Bennett, R.  
712 Pajon, C. Knightly, B. Leav, W. Deng, H. Zhou, S. Han, M. Ivarsson, J. Miller, T. Zaks,  
713 C. S. Group, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J*  
714 *Med* **384**, 403-416 (2021).
- 715 18. S. H. Hodgson, K. Mansatta, G. Mallett, V. Harris, K. R. W. Emary, A. J. Pollard, What  
716 defines an efficacious COVID-19 vaccine? A review of the challenges assessing the  
717 clinical efficacy of vaccines against SARS-CoV-2. *Lancet Infect Dis* **21**, e26-e35 (2021).
- 718 19. P. Jin, J. Li, H. Pan, Y. Wu, F. Zhu, Immunological surrogate endpoints of COVID-2019  
719 vaccines: the evidence we have versus the evidence we need. *Signal Transduct Target*  
720 *Ther* **6**, 48 (2021).
- 721 20. J. H. Kim, F. Marks, J. D. Clemens, Looking beyond COVID-19 vaccine phase 3 trials.  
722 *Nat Med* **27**, 205-211 (2021).
- 723 21. K. McMahan, J. Yu, N. B. Mercado, C. Loos, L. H. Tostanoski, A. Chandrashekar, J.  
724 Liu, L. Peter, C. Atyeo, A. Zhu, E. A. Bondzie, G. Dagotto, M. S. Gebre, C. Jacob-Dolan,  
725 Z. Li, F. Nampanya, S. Patel, L. Pessaint, A. Van Ry, K. Blade, J. Yalley-Ogunro, M.  
726 Cabus, R. Brown, A. Cook, E. Teow, H. Andersen, M. G. Lewis, D. A. Lauffenburger, G.  
727 Alter, D. H. Barouch, Correlates of protection against SARS-CoV-2 in rhesus macaques.  
728 *Nature* **590**, 630-634 (2021).
- 729 22. A. Addetia, K. H. D. Crawford, A. Dingens, H. Zhu, P. Roychoudhury, M. L. Huang, K.  
730 R. Jerome, J. D. Bloom, A. L. Greninger, Neutralizing Antibodies Correlate with

- 731 Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High  
732 Attack Rate. *J Clin Microbiol* **58**, (2020).
- 733 23. M. Voysey, S. A. Costa Clemens, S. A. Madhi, L. Y. Weckx, P. M. Folegatti, P. K. Aley,  
734 B. Angus, V. L. Baillie, S. L. Barnabas, Q. E. Bhorat, S. Bibi, C. Briner, P. Cicconi, E. A.  
735 Clutterbuck, A. M. Collins, C. L. Cutland, T. C. Darton, K. Dheda, C. Dold, C. J. A.  
736 Duncan, K. R. W. Emary, K. J. Ewer, A. Flaxman, L. Fairlie, S. N. Faust, S. Feng, D. M.  
737 Ferreira, A. Finn, E. Galiza, A. L. Goodman, C. M. Green, C. A. Green, M. Greenland,  
738 C. Hill, H. C. Hill, I. Hirsch, A. Izu, D. Jenkin, C. C. D. Joe, S. Kerridge, A. Koen, G.  
739 Kwatra, R. Lazarus, V. Libri, P. J. Lillie, N. G. Marchevsky, R. P. Marshall, A. V. A.  
740 Mendes, E. P. Milan, A. M. Minassian, A. McGregor, Y. F. Mujadidi, A. Nana, S. D.  
741 Padayachee, D. J. Phillips, A. Pittella, E. Plested, K. M. Pollock, M. N. Ramasamy, A. J.  
742 Ritchie, H. Robinson, A. V. Schwarzbald, A. Smith, R. Song, M. D. Snape, E. Sprinz, R.  
743 K. Sutherland, E. C. Thomson, M. E. Torok, M. Toshner, D. P. J. Turner, J. Vekemans,  
744 T. L. Villafana, T. White, C. J. Williams, A. D. Douglas, A. V. S. Hill, T. Lambe, S. C.  
745 Gilbert, A. J. Pollard, C. V. T. G. Oxford, Single-dose administration and the influence of  
746 the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19  
747 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* **397**, 881-891  
748 (2021).
- 749 24. W. F. Garcia-Beltran, E. C. Lam, M. G. Astudillo, D. Yang, T. E. Miller, J. Feldman, B.  
750 M. Hauser, T. M. Caradonna, K. L. Clayton, A. D. Nitido, M. R. Murali, G. Alter, R. C.  
751 Charles, A. Dighe, J. A. Branda, J. K. Lennerz, D. Lingwood, A. G. Schmidt, A. J.  
752 Iafate, A. B. Balazs, COVID-19-neutralizing antibodies predict disease severity and  
753 survival. *Cell* **184**, 476-488 e411 (2021).
- 754 25. H. F. Sewell, R. M. Agius, D. Kendrick, M. Stewart, Covid-19 vaccines: delivering  
755 protective immunity. *BMJ* **371**, m4838 (2020).
- 756 26. B. S. Graham, Rapid COVID-19 vaccine development. *Science* **368**, 945-946 (2020).
- 757 27. B. F. Haynes, L. Corey, P. Fernandes, P. B. Gilbert, P. J. Hotez, S. Rao, M. R. Santos, H.  
758 Schuitemaker, M. Watson, A. Arvin, Prospects for a safe COVID-19 vaccine. *Sci Transl*  
759 *Med* **12**, (2020).
- 760 28. Z. Chen, E. John Wherry, T cell responses in patients with COVID-19. *Nat Rev Immunol*  
761 **20**, 529-536 (2020).
- 762 29. N. Vabret, G. J. Britton, C. Gruber, S. Hegde, J. Kim, M. Kuksin, R. Levantovsky, L.  
763 Malle, A. Moreira, M. D. Park, L. Pia, E. Risson, M. Saffern, B. Salome, M. Esai Selvan,  
764 M. P. Spindler, J. Tan, V. van der Heide, J. K. Gregory, K. Alexandropoulos, N.  
765 Bhardwaj, B. D. Brown, B. Greenbaum, Z. H. Gumus, D. Homann, A. Horowitz, A. O.  
766 Kamphorst, M. A. Curotto de Lafaille, S. Mehandru, M. Merad, R. M. Samstein, P. Sinai  
767 Immunology Review, Immunology of COVID-19: Current State of the Science. *Immunity*  
768 **52**, 910-941 (2020).
- 769 30. D. Ho, P. Wang, L. Liu, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P.  
770 Kwong, B. Graham, J. Mascola, J. Chang, M. Yin, M. Sobieszczyk, C. Kyratsous, L.  
771 Shapiro, Z. Sheng, M. Nair, Y. Huang, Increased Resistance of SARS-CoV-2 Variants  
772 B.1.351 and B.1.1.7 to Antibody Neutralization. *Res Sq*, (2021).
- 773 31. C. K. Wibmer, F. Ayres, T. Hermanus, M. Madzivhandila, P. Kgagudi, B. Oosthuysen,  
774 B. E. Lambson, T. de Oliveira, M. Vermeulen, K. van der Berg, T. Rossouw, M. Boswell,  
775 V. Ueckermann, S. Meiring, A. von Gottberg, C. Cohen, L. Morris, J. N. Bhiman, P. L.

- 776 Moore, SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19  
777 donor plasma. *Nat Med*, (2021).
- 778 32. K. Wu, A. P. Werner, J. I. Moliva, M. Koch, A. Choi, G. B. E. Stewart-Jones, H. Bennett,  
779 S. Boyoglu-Barnum, W. Shi, B. S. Graham, A. Carfi, K. S. Corbett, R. A. Seder, D. K.  
780 Edwards, mRNA-1273 vaccine induces neutralizing antibodies against spike mutants  
781 from global SARS-CoV-2 variants. *bioRxiv*, (2021).
- 782 33. S. P. Buchbinder, D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B.  
783 Gilbert, J. R. Lama, M. Marmor, C. Del Rio, M. J. McElrath, D. R. Casimiro, K. M.  
784 Gottesdiener, J. A. Chodakewitz, L. Corey, M. N. Robertson, T. Step Study Protocol,  
785 Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a  
786 double-blind, randomised, placebo-controlled, test-of-concept trial. *Lancet* **372**, 1881-  
787 1893 (2008).
- 788 34. S. Zhang, W. Huang, X. Zhou, Q. Zhao, Q. Wang, B. Jia, Seroprevalence of neutralizing  
789 antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-  
790 68 in healthy Chinese adults. *J Med Virol* **85**, 1077-1084 (2013).
- 791 35. E. Zielinska, D. Liu, H. Y. Wu, J. Quiroz, R. Rappaport, D. P. Yang, Development of an  
792 improved microneutralization assay for respiratory syncytial virus by automated plaque  
793 counting using imaging analysis. *Virol J* **2**, 84 (2005).
- 794 36. M. Aste-Amezaga, A. J. Bett, F. Wang, D. R. Casimiro, J. M. Antonello, D. K. Patel, E.  
795 C. Dell, L. L. Franlin, N. M. Dougherty, P. S. Bennett, H. C. Perry, M. E. Davies, J. W.  
796 Shiver, P. M. Keller, M. D. Yeager, Quantitative adenovirus neutralization assays based  
797 on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies  
798 and in the design of adenovector vaccines. *Hum Gene Ther* **15**, 293-304 (2004).

799

## 800 **GRAd study group:**

801 Sandrine Ottou (INMI), Serena Vita (INMI), Alessandra Vergori (INMI), Alessandra D'Abramo  
802 (INMI), Antonella Petrecchia (INMI), Chiara Montaldo (INMI), Emilio Scalise (INMI),  
803 Germana Grassi (INMI), Rita Casetti (INMI), Veronica Bordoni (INMI), Stefania Notari (INMI),  
804 Francesca Colavita (INMI), Silvia Meschi (INMI), Daniele Lapa (INMI), Licia Bordi (INMI),  
805 Silvia Murachelli (INMI), Teresa Tambasco (INMI), Alessandra Grillo (INMI), Erminia Masone  
806 (INMI), Elisa Marchioni (INMI), Dorian Bardhi (INMI), Ottavia Porzio (Ospedale Pediatrico  
807 Bambino Gesù), Francesca Cocca (Ospedale Pediatrico Bambino Gesù), Silvia Murachelli (INMI),  
808 Irene Turrini (CRC-Verona), Feliciano Malescio (CRC-Verona), Luigi Ziviani (CRC-Verona),  
809 Rita Lawlor (CRC-Verona), Federica Poli (CRC-Verona), Federica Martire (CRC-Verona),  
810 Daniela Zamboni (CRC-Verona), Flavia Mazzaferri (CRC-Verona).

811

## 812 **Acknowledgments:**

813 This Phase 1 study was through the participation of clinical trial volunteers. We are profoundly  
814 grateful to the volunteers for their effort.

815 We are grateful to the members of the Phase 1 Committee at the National Institute of health  
816 (ISS), of the technic-scientific committee of the Italian Drug Regulatory Agency (AIFA) and to  
817 the National Ethical Board for COVID-19.

818 We thank the members of the Data Safety and Monitoring Board for the priceless efforts spent  
819 for supporting the investigators on assessing information and for advising on trial continuation:  
820 Franco Locatelli (President), Paolo Antonio Grossi (Member), Sergio Bonini (Member) and  
821 Paolo Bruzzi (Member).

822 We thank the Prof. Rino Rappuoli for the support for interpretation of the interim analysis  
823 results.

824 We finally thank the ReiThera GMP and PD staff.

#### 825 **Funding:**

826 The phase 1 study has been funded by Regione Lazio and Italian Ministry of research.

827 INMI authors are supported by the Italian Ministry of Health (Ricerca Corrente line 1, COVID-  
828 2020-12371735 and COVID-2020- 12371817).

#### 829 **Author contributions:**

830 Conceptualization: SL, SCa, AF, GI. Methodology: SL, SCa, AA, SM, EN, RC, CA, CC, SB,  
831 EG, GI, AF, GK, AV, SCo, MM, YS. Investigation: SL, SCa, AA, SM, EN, CA, CC, FG, SB,  
832 ASo, AMC, FB, MG, AR, ASa, GM, RG, EC, LS, MMP, ADL, EG, GK, MP. Visualization: SL,  
833 SCa

834 Funding acquisition: GI, EG, SCo, AF, MP. Project administration: FM, MMP, EG, FV, MS.  
835 Supervision: GI, FV, VA, FN, AV, AF, SCo. MRC. Writing – original draft: SL, SCa. Writing –  
836 review & editing: CA, CC, GK, MM, AV, GI, AF.

#### 837 **Competing interests:**

838 SCa, RC, FM, VA, FG, FN, MS, SB, ASo, AMC, FB, MG, AR, AV, SCo and AF are employees  
839 of ReiThera Srl. AF and SCo are also shareholders of Keires AG. SCo, AR, and AV are  
840 inventors of the Patent Application No. 20183515.4 titled “GORILLA ADENOVIRUS



841 NUCLEIC ACID- AND AMINO ACID-SEQUENCES, VECTORS CONTAINING SAME,  
842 AND USES THEREOF”. All remaining authors declare that they have no competing interests.

843 **Data and materials availability:**

844 All data are available in the main text or the supplementary materials. This trial is registered with  
845 ClinicaTrials.gov, NCT04528641.